ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

USNA vs OBIO // EV/EBITDA & P/E VALUATION

USANA Health Sciences Inc. (NYSE) VS. Orchestra BioMed Holdings Inc. (NASDAQ) • 15-METRIC TALLY: USNA 6 — OBIO 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (USNA VS. OBIO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC USNA OBIO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 78.30% 96.00% -17.70 OBIO /gross-margins <GO>
Return on Invested Capital (ROIC) 7.90% -35.00% +42.90 USNA /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 2.7x — — TIE /valuation <GO>
Free Cash Flow Yield 3.22% -13.51% +16.73 USNA /fcf-yield <GO>
Operating Margin 4.00% -60.00% +64.00 USNA /operating-margins <GO>
Net Profit Margin 1.20% -60.00% +61.20 USNA /net-margins <GO>
Revenue Growth (YoY) 8.30% 180.00% -171.70 OBIO /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.56 0.20 +3.36 USNA /balance-sheet <GO>
Piotroski F-Score Quality 7/9 5/9 +2.00 USNA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.3 53.6 -8.31 OBIO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 22.9x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $265.0M $366.0M -$101.1M OBIO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR USNA REV OBIO REV USNA GROSS % OBIO GROSS % USNA FCF OBIO FCF
FY 2025 $925.3M $33.5M 78.3% 98.0% $8.5M -$49.5M
FY 2024 $854.5M $2.6M 81.1% 92.3% $50.9M -$50.8M
FY 2023 $921.0M $2.8M — — $70.6M -$46.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
USNA // BETA —
OBIO // BETA —